Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.6K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.0K
6.0K
Rh Blood Group01:19

Rh Blood Group

4.2K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
4.2K
Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

5.1K
Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
5.1K
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

2.2K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
2.2K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

493
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
493

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New dosing regimen of oral iron for iron deficiency anaemia in children.

Archives of disease in childhood·2025
Same author

Prescribing liquid medication: can the dose be accurately given?

Archives of disease in childhood·2013
Same author

Inpatients' expectations and experiences of hospital pharmacy services: qualitative study.

Health expectations : an international journal of public participation in health care and health policy·2013
Same author

Prescribing for children.

International emergency nursing·2011
Same author

The pros and cons of electronic prescribing for children.

Archives of disease in childhood·2011

Related Experiment Video

Updated: Mar 31, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.6K

Where are we with RSV prophylaxis?

Neil A Caldwell1, Ceri Townsend2

  • 1Department of Pharmacy, Wirral University Teaching Hospital NHS Foundation Trust, Wirral, UK.

Archives of Disease in Childhood. Education and Practice Edition
|October 30, 2015
PubMed
Summary
This summary is machine-generated.

Respiratory syncytial virus (RSV) causes severe illness in young children. While prophylaxis exists, its high cost and infrastructure needs limit access, especially in low-income nations where RSV mortality is highest.

Keywords:
General PaediatricsImmunisationInfectious DiseasesVirology

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

17.6K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.4K

Related Experiment Videos

Last Updated: Mar 31, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.6K
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

17.6K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.4K

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Public Health

Background:

  • Respiratory syncytial virus (RSV) is a leading cause of respiratory illness and death in infants under 24 months.
  • RSV infections exhibit predictable seasonal patterns, contributing significantly to childhood morbidity and mortality globally.
  • Existing prophylactic measures, available since 1998, reduce hospitalizations in high-risk infants.

Purpose of the Study:

  • To review the pathophysiology and risk factors associated with RSV infections in young children.
  • To provide an overview of current pharmacological prophylaxis and prevention strategies for RSV.
  • To highlight the accessibility challenges of existing RSV prophylaxis in resource-limited settings.

Main Methods:

  • Literature review of RSV pathophysiology and epidemiology.
  • Analysis of available RSV prophylaxis and prevention agents.
  • Discussion of socioeconomic factors impacting access to care.

Main Results:

  • RSV poses a substantial health burden, particularly for infants under two years old.
  • Current pharmacological prophylaxis is effective but costly and infrastructure-dependent.
  • Access to prophylaxis is severely limited in low- and middle-income countries where RSV mortality is highest.

Conclusions:

  • Understanding RSV pathophysiology and risk factors is crucial for targeted prevention.
  • The high cost and logistical demands of current prophylaxis hinder its widespread use, especially in developing nations.
  • Further research and innovative strategies are needed to improve global access to RSV prevention and reduce childhood mortality.